In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma
Authors:
- Alex Y. ChangACAlex Y. Chang
- Miao WangMWMiao Wang
- 1 March 2013
- journal article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 24 (3) , 251-259
Abstract
Hepatocellular carcinoma (HCC) is one of the most common and challenging malignant disease. The prognosis is poor in patients with advanced disease. Although sorafenib prolongs survival in these patients, improvement remains modest. We used doxorubicin and sorafenib as controls and screened eight new agents including ixabepilone, gefitinib, cetuximab, brivanib, dasatinib, sunitinib, BMS-690514, and BMS-536924 against nine HCC cell lines and evaluated their interactions. We studied growth inhibition of 10 drugs against nine HCC cell lines. Single-agent activity was tested using an MTS assay. Combination studies were carried out in both resistant and sensitive cells to determine the combination index. The IC50 of each agent varied widely among nine cell lines. Ixabepilone was more potent than doxorubicin. HT-17 cells were more sensitive to gefitinib and cetuximab than the other eight cell lines. BMS-536924 showed good efficacy (IC50 ≤ 1 µmol/l) on all three α-fetoprotein (AFP)-producing cell lines (HepG2, Hep3B, Huh-7). Three cell lines showed moderate sensitivity to dasatinib (IC50 ≤ 1 µmol/l). Dasatinib showed the most frequent and strongest synergism with ixabepilone, gefitinib, brivanib, BMS-690514, or BMS-536924. Ixabepilone, sorafenib, brivanib, dasatinib, and BMS-536924 are active against HCC cell lines. The heterogeneity of the sensitivity of each cell line emphasizes the need for individualized treatment. The sensitivity to BMS-536924 is closely associated with the production of AFP. AFP may be a biomarker predicting response to the insulin-like growth factor-1 receptor inhibitor in HCC patients. Additional studies are warranted. The synergism between dasatinib and other agents also provides future research directions to understand drug resistance and improve outcome.Keywords
This publication has 36 references indexed in Scilit:
- An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinomaInvestigational New Drugs, 2010
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular CarcinomaJournal of Clinical Oncology, 2008
- Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinomaCancer, 2007
- Phase 2 study of cetuximab in patients with advanced hepatocellular carcinomaCancer, 2007
- Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular CancerJournal of Clinical Oncology, 2005
- Hepatocellular Carcinoma: The Need for ProgressJournal of Clinical Oncology, 2005
- Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2005
- Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survivalHepatology, 2003